pharma · Relapsed/Refractory Diffuse Large B-cell Lymphoma · Non-muscle invasive bladder cancer (NMIBC)
Shanghai Antengene Corporation
Shanghai Antengene Corporation Limited
Shanghai Antengene Corporation trial registry — 3 ClinicalTrials.gov studies with program phase, status, and indication context.
SAINT-LAURENT, CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- SAINT-LAURENT, CN
- Programs
- 3
- Drugs
- 8
- Patents
- 53
Shanghai Antengene Corporation clinical trials
Registry index of 3 ClinicalTrials.gov studies linked to Shanghai Antengene Corporation programs — each row shows trial ID, program name, phase, status, and indication.
Shanghai Antengene Corporation trial registry — 3 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Shanghai Antengene Corporation.
-
EG-70-101 — Phase 2
Clinical update -
EG-70 (phase 1) — Phase 2
Clinical update -
ATG-010 and ATG-008 — Phase 1
Clinical update -
Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
Patent grant -
Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
Patent grant -
Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
Patent grant -
Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
Patent grant -
Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
Patent grant